An interventional study of umami and bitter in Obesity, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science
Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg (bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides CCK and GLP-1.
Study design: To assess the effect of intraduodenal infusion of single ingredients and a combination of tastants (bitter, umami and sweet) on ad libitum food intake.
Secondary Objective(s):
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 15 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
intraduodenal infusion of umami
Dietary Supplement: umami
intraduodenal infusion of sweet tastant
Dietary Supplement: sweet
intraduodenal infusion of bitter tastant
Dietary Supplement: bitter
intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
Dietary Supplement: umami · Dietary Supplement: bitter · Dietary Supplement: sweet
intraduodenal infusion of placebo (tap water)
intraduodenal infusion of umami tastant
intraduodenal infusion of bitter tastant
intraduodenal infusion of sweet tastant
Ad libitum meal intake
Difference in ad libitum meal intake (as measured during ad libitum pasta meal). At end of the testday
Time frame: 5 weeks
Satiation
Difference in satiation (as measured by VAS) per time point
Time frame: 5 weeks
Gut hormones
Measurements in plasma levels of the gut hormones CCK, GLP-1, insulin and glucose
Time frame: 5 weeks
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center